Faster global financial news!
Exelixis
-
Exelixis (EXEL) stock dropped after FDA delayed potential approval of its new colon cancer treatment by three months
Exelixis (EXEL) stock dropped out of a buy zone Friday after the Food and Drug Administration delayed the potential approval of its new colon cancer treatment by three months. The combination includes
-
IBD: Exelixis (EXEL) Stock Breaks Out After Earnings Resistance, Up 0.08% Intraday to $59.08
IBD notes that Exelixis stock broke out past a 57.57 USD flat-base buy point, with the buy range extending up to 60.45 USD. The stock holds an IBD Composite Rating of 99/99 and an industry group rank
-
Exelixis (EXEL), a cancer treatment company, saw its stock price hit a new all-time high on Wednesday, as the market focused on a key FDA action.
Exelixis (EXEL), a cancer treatment company, saw its stock price hit a new all-time high on Wednesday, as the market focused on a key FDA action.
-
Exelixis (EXEL) stock fell early Thursday after the biotechnology company reported mixed second-quarter earnings, with sales of its core cancer drug cabozantinib missing expectations.
The company's cancer drug Cabometyx had quarterly sales of $570.6 million.
-
Exelixis (EXEL) stock dropped after FDA delayed potential approval of its new colon cancer treatment by three months
Exelixis (EXEL) stock dropped out of a buy zone Friday after the Food and Drug Administration delayed the potential approval of its new colon cancer treatment by three months. The combination includes
-
IBD: Exelixis (EXEL) Stock Breaks Out After Earnings Resistance, Up 0.08% Intraday to $59.08
IBD notes that Exelixis stock broke out past a 57.57 USD flat-base buy point, with the buy range extending up to 60.45 USD. The stock holds an IBD Composite Rating of 99/99 and an industry group rank
-
Exelixis (EXEL), a cancer treatment company, saw its stock price hit a new all-time high on Wednesday, as the market focused on a key FDA action.
Exelixis (EXEL), a cancer treatment company, saw its stock price hit a new all-time high on Wednesday, as the market focused on a key FDA action.
-
Exelixis (EXEL) stock fell early Thursday after the biotechnology company reported mixed second-quarter earnings, with sales of its core cancer drug cabozantinib missing expectations.
The company's cancer drug Cabometyx had quarterly sales of $570.6 million.
- No data
Exelixis
24H Trending
-
1
ETH (Ethereum) surged 5.31% in 1 hour, currently trading at $2,439.61
-
2
Why are various blockchain protocols launching native stablecoins?
-
3
Wingtech rejects Nexperia restructuring, cites ‘discrimination’ towards Chinese investors
-
4
What Elements Are Included in Tokenomics? How to Use It to Identify Valuable Digital Currencies
-
5
How to buy and sell HERO? First distinguish the project, then check the listing channels
-
6
CVS Health plans to split into two independent publicly traded companies by early 2028, reversing its $78 billion acquisition of Aetna.
-
7
DeFi Losses Nearing $600M in a Single Month: April 2026 Security Incidents Sound Alarm Bells for Cross-Chain and Governance
-
8
Cosmos (ATOM) Outlook Analysis: Tokenomics Restructuring and Cross-Chain Upgrades
-
9
WSJ: New York gold futures rose 2.3% in early European trading to $4,032.90 per troy ounce.
-
10
Where to Find Reliable USDT Trading Software: Top Exchange References and Selection Criteria
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
